Voices from China at ASCO | Professor Kun Wang Unveils Landmark neoCARHP Study: “Carboplatin-Free” Strategy Redefines Treatment for HER2-Positive Breast Cancer

Voices from China at ASCO | Professor Kun Wang Unveils Landmark neoCARHP Study: “Carboplatin-Free” Strategy Redefines Treatment for HER2-Positive Breast Cancer

2025.07.08
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this high-profile event, Professor Kun Wang from Guangdong Provincial People’s Hospital presented the much-anticipated results of the neoCARHP study (Abstract LBA500) during an oral session. The study, which focuses on early-stage HER2-positive breast cancer, offers an innovative head-to-head comparison between a carboplatin-free THP regimen and the traditional carboplatin-containing TCbHP regimen. The findings revealed that the THP regimen was non-inferior to TCbHP in terms of pathological complete response (pCR), with a significantly better toxicity profile. This important discovery not only provides a new therapeutic option for patients with HER2-positive breast cancer but also reflects a patient-centered approach to treatment—marking a shift toward more precise and individualized care. Following the presentation, Oncology Frontier interviewed Professor Wang to discuss the study’s background, significance, and what the future holds for HER2-positive breast cancer treatment.
Tracing ASCO丨Professor Yongmei Yin: OptiTROP-Breast05 Study Selected for Oral Presentation, Domestic TROP2 ADC Once Again in the Spotlight

Tracing ASCO丨Professor Yongmei Yin: OptiTROP-Breast05 Study Selected for Oral Presentation, Domestic TROP2 ADC Once Again in the Spotlight

2025.07.08
Sacituzumab Tirumotecan (sac-TMT) is a novel TROP2-targeted ADC independently developed in China. Over the past two years, its clinical findings have been frequently presented at major international conferences and published in top-tier journals. At the 2025 ASCO Annual Meeting, Professor Yongmei Yin from Jiangsu Provincial People’s Hospital delivered a Rapid Oral Abstract presentation on the phase II OptiTROP-Breast05 study, which evaluated sac-TMT as a first-line therapy for advanced triple-negative breast cancer (TNBC). The results demonstrated impressive efficacy and a favorable safety profile. Oncology Frontier invited Professor Yongmei Yin at the conference to discuss the study's key outcomes and how sac-TMT, as a leading TROP2 ADC, is poised to make a lasting impact on breast cancer treatment in China and globally.
Professor Linhui Wang: The “Changhai Experience” in Clinical Research and Practice of Urologic Oncology | CUDA 2025

Professor Linhui Wang: The “Changhai Experience” in Clinical Research and Practice of Urologic Oncology | CUDA 2025

2025.07.08
The 2025 Annual Meeting of the Chinese Urological Doctors Association (CUDA) was successfully held from June 12 to 15 in the romantic city of Zhuhai. With the theme “Healthy China, Urology in Action,” the conference gathered urological professionals from across the country to share cutting-edge knowledge and practical experience in the field. Professor Linhui Wang from the Department of Urology at Changhai Hospital, the First Affiliated Hospital of the Naval Medical University (Shanghai), shared with Oncology Frontier – UroStream the achievements and clinical insights of his team in genitourinary oncology.